What Tavros Therapeutics does

Tavros Therapeutics is a preclinical-stage biotechnology company founded in 2019 and headquartered in Durham, North Carolina. The company develops a proprietary genomics platform designed to systematically identify genetic vulnerabilities in tumors, with the stated goal of generating targets for precision cancer therapeutics. Rather than screening compounds against broad cancer phenotypes, the platform analyzes tumor genetic weaknesses to nominate specific targets that can be exploited by targeted therapies — positioning Tavros as a target-discovery engine rather than a CRO or platform licensor at the current stage.

The business model is structured around therapeutic development and, eventually, potential licensing of platform technologies or pipeline assets. Tavros is pre-revenue with no disclosed customers, contracts, or licensing arrangements. Operations have been funded entirely by venture capital: an initial ~$3.0 million round from Piedmont Capital Investments in March 2020, a $7.5 million oversubscribed Seed II in September 2022 co-led by Piedmont Capital Investments and KdT Ventures with participation from Alexandria Venture Investments, and a $17.5 million financing in October 2022 led by Vividion Therapeutics. The end customer segment is healthcare and pharmaceutical — specifically oncology drug developers and, ultimately, cancer patients — but the company is still upstream of commercial drug development. The company is led by co-founder and CEO Eoin McDonnell, co-founder and Chief Business Officer Greg Mossinghoff, and co-founder Kris Wood.

The company operated at a headcount of 11–50 employees and, as of the input snapshot, the corporate domain tavrostherapeutics.com is listed for sale on HugeDomains for $2,995. No company-controlled website content, recent press, product updates, clinical milestones, or board disclosures are present in the source material beyond the 2022 financing events, which together indicate an ambiguous operational status and represent a material risk signal for any prospective investor or acquirer.

Name

Tavros Therapeutics

Website

https://tavrostherapeutics.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

Tavros Therapeutics is a preclinical-stage biotechnology company based in Durham, North Carolina, developing a proprietary genomics platform that identifies genetic vulnerabilities in tumors to guide targeted oncology therapy development.

Ownership category

akta.pro rank

Product category

Oncology Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies) (HLAAANAK)

Keywords

• Cancer therapeutics
• Oncology drug discovery
• Genomics platform
• Targeted cancer therapies
• Tumor vulnerability identification

Headquarters

HQ city

Durham

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel

Revenue model

1. Therapeutic Development: Pre-revenue biotech company developing targeted cancer therapies through its genomics platform. Revenue generation expected through therapeutic development and potential licensing of platform technologies.

Core offering

Tavros Therapeutics is an emerging biotechnology company that discovers and develops targeted therapies for cancer. It operates a proprietary genomics platform that identifies genetic vulnerabilities in tumors and exploits them to develop targeted oncology treatments.

Product overview

Tavros Therapeutics is a biotech company developing a genomics platform for identifying cancer vulnerabilities and targeted therapies. The company's core technology is its genomics platform, which analyzes tumor genetic weaknesses to discover targets for cancer treatment development. The company operates in the oncology therapeutics space rather than as a traditional software product company.

Differentiator

Problem solved

Functional benefit

Products and services

• Genomics Platform A proprietary genomics platform that identifies vulnerabilities and genetic weaknesses in tumors to support the development of targeted cancer therapies. Used internally to discover targets for oncology drug development.

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators1 record

Recent moves3 records

Expansion highlights3 records

Direct peers

• Relay Therapeutics: Relay Therapeutics is a clinical-stage precision medicine company that uses motion-based protein design and genomics to develop targeted oncology therapies. It is a direct competitor in the precision oncology platform space targeting genomically-defined cancer vulnerabilities.
• Repare Therapeutics: Repare Therapeutics applies synthetic lethality and genome-wide CRISPR screens to identify precision oncology targets — closely aligned with Tavros' approach of identifying tumor vulnerabilities via genomics to develop targeted cancer therapies.
• Vividion Therapeutics: Vividion is a proteomics-based drug discovery company that made a $17.5M investment in Tavros. While focused on covalent chemistry and proteomics rather than genomics, Vividion operates in the same precision oncology drug discovery space and has likely absorbed Tavros' capabilities, making it the most directly comparable entity.
• Black Diamond Therapeutics: Black Diamond Therapeutics is a clinical-stage precision oncology company using its discovery platform to identify and develop allosteric mutation-targeted therapies. It is a direct peer in platform-driven, genomics-based targeted cancer therapy development.
• Tango Therapeutics: Tango Therapeutics is a clinical-stage biotechnology company using synthetic lethality and DNA damage response approaches to develop precision oncology therapies. Tango's product platform for identifying tumor vulnerabilities using genomics directly parallels Tavros' core technology and target identification approach.

Emerging players

• Foghorn Therapeutics: Foghorn Therapeutics applies chromatin biology and gene regulation insights to develop oncology therapeutics. It is comparable to Tavros as an emerging platform-based precision oncology company with proprietary biology-driven discovery capabilities.
• Erasca: Erasca is a clinical-stage precision oncology company developing therapies for RAS/MAPK pathway-driven cancers. While targeting a specific pathway rather than a broader vulnerability platform, Erasca is comparable as a precision oncology company using genomics-driven target selection.
• Volastra Therapeutics: Volastra Therapeutics is an early-stage precision oncology company focused on exploiting chromosomal instability in cancer. While its vulnerability focus differs mechanistically, it shares Tavros' underlying thesis of identifying tumor-specific vulnerabilities for targeted therapy development.

Broad incumbents

• Recursion Pharmaceuticals: Recursion is an established AI-driven drug discovery company with oncology programs. As a broader platform player in computational biology-driven target identification, it represents a comparable larger incumbent working on platform-based therapeutic discovery, though with different underlying technology.
• Schrödinger: Schrödinger is a larger computational drug discovery company with significant operations in oncology. While broader in scope and using physics-based computational methods rather than genomics-led vulnerability screens, it competes for the same precision oncology partnership and capital opportunities as Tavros.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds3 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tavros Therapeutics